BigHat Biosciences

Company profile

About BigHat Biosciences

BigHat Biosciences is a Series B biotechnology company that develops next-generation antibody therapeutics using an integrated machine learning and synthetic biology platform. Founded in 2019 and headquartered in San Mateo, California, the company has raised over $100 million from top investors to pursue its mission of creating safer, more effective antibody therapies for patients. The company's proprietary Milliner platform combines a synthetic biology-based high-speed wet lab with state-of-the-art machine learning technologies into a full-stack antibody discovery and engineering system. At the heart of this platform is Reccy Antibody Design Studio (RADS), an AI-driven system that orchestrates thousands of models and datasets through continuous design-build-test cycles. The platform can synthesize, purify, and fully characterize hundreds of recombinant antibodies for biophysics and function in a single weekly workcell, dramatically accelerating the path from hypothesis to development candidate. BigHat's technology addresses the complex challenges of antibody therapeutic development, including affinity, specificity, stability, manufacturability, and immunogenicity. The company applies its capabilities to both wholly-owned therapeutic programs and strategic partnerships with leading pharmaceutical companies including Eli Lilly, Johnson & Johnson, and Lonza's Synaffix. By leveraging cell-free protein synthesis, automated assays, and iterative machine learning optimization, BigHat is advancing treatments for today's most challenging diseases, from inflammation and infections to cancers.

Company description · BigHat Biosciences official website